J&J Accepts $4 Billion Offer From Carlyle for Ortho Unit

Johnson & Johnson (JNJ) accepted the $4 billion offer from Carlyle Group LP (CG) made in January to acquire the health-care products company’s only diagnostics division.

The acceptance comes after consultation with relevant works councils and trade unions, New Brunswick, New Jersey-based J&J said in a statement today. The unit, for sale since November, had $1.89 billion in sales last year, or about 2.6 percent of J&J’s revenue.

J&J has said that it’s goals are to be the first or second biggest in areas where it competes or to own businesses complementary to other J&J units. Today’s move is part of an industry trend in which Pfizer Inc. and Merck & Co. have sold or may sell off secondary units to focus on primary businesses.

Carlyle, based in Washington, plans on operating the medical diagnostics business as a stand-alone company, said people with knowledge of the matter in January. The unit makes blood tests to screen for diseases.

Today was the deadline for J&J to accept the deal announced on Jan. 16, the company said. J&J had received two other offers for the division, people familiar with the situation said in December: a joint bid from Blackstone Group LP (BX) and Danaher Corp., and a combined offer from CVC Capital Partners Ltd. and Leonard Green & Partners LP.

Photographer: Simon Dawson/Bloomberg

Johnson & Johnson accepted the $4 billion offer from The Carlyle Group made in January to acquire the company’s Ortho-Clinical Diagnostics business. Close

Johnson & Johnson accepted the $4 billion offer from The Carlyle Group made in January... Read More

Close
Open
Photographer: Simon Dawson/Bloomberg

Johnson & Johnson accepted the $4 billion offer from The Carlyle Group made in January to acquire the company’s Ortho-Clinical Diagnostics business.

The deal should close near the middle of this year, J&J said in the statement. J&J rose less than 1 percent to $98.23 at 4 p.m. New York time.

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Bruce Rule

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.